Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Howard Rosen?

Howard M. Rosen

Vice President, Cell Processing

Haemonetics Corporation

HQ Phone:  (781) 848-7100

Direct Phone: (781) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Haemonetics Corporation

400 Wood Road

Braintree, Massachusetts,02184

United States

Company Description

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important med... more.

Find other employees at this company (3,489)

Background Information

Employment History

Director, Cardiovascular Service Line Franchise, CRV

Boston Scientific Corporation


Sales and Product Management Roles

Medis Technologies Ltd.


Vice President, Sales and Marketing

BG Medicine Inc


Web References(5 Total References)


Management | BG Medicine Corporate Site

investor.bg-medicine.com [cached]

Howard Rosen
Vice President, Sales and Marketing Mr. Rosen joins BG Medicine from a two decade tenure in Sales and Marketing with Boston Scientific, where he most recently held the position of Director, Cardiovascular Service Line Franchise in the Cardiology, Rhythm and Vascular (CRV) Division where he led marketing strategies and channel activities. Previously at Boston Scientific, he held positions of increasing responsibility, including sales, product management, Group Marketing Manager, Director, and Global Carotid Endovascular Therapies for the Medi-tech and Peripheral Vascular Divisions. Prior to Boston Scientific, Mr. Rosen held sales and product management roles with Medi-tech. Mr. Rosen holds a B.S. in Business Administration from Northeastern University.


www.galectin-3.com

Howard Rosen
Vice President, Sales and Marketing Howard Rosen Vice President, Sales and Marketing Mr. Rosen joins BG Medicine from a two decade tenure in Sales and Marketing with Boston Scientific, where he most recently held the position of Director, Cardiovascular Service Line Franchise in the Cardiology, Rhythm and Vascular (CRV) Division where he led marketing strategies and channel activities. Previously at Boston Scientific, he held positions of increasing responsibility, including sales, product management, Group Marketing Manager, Director, and Global Carotid Endovascular Therapies for the Medi-tech and Peripheral Vascular Divisions. Prior to Boston Scientific, Mr. Rosen held sales and product management roles with Medi-tech. Mr. Rosen holds a B.S. in Business Administration from Northeastern University.


ImagingBIz.com E-Newsletter - Volume 2, Number 4

www.imagingcenterinstitute.com [cached]

Quoting Howard Rosen of Boston Scientific, the article states that Medicare covers just 5% to 7% of beneficiaries with carotid artery disease, and that the expanded coverage would include between 15% and 20% of beneficiaries.


video.clintonglobalinitiative.org

Under current policy, Medicare covers the new procedure for between 5% and 7% of beneficiaries with carotid artery disease, and the expansion under consideration by CMS would increase the rate to between 15% and 20%, according to Howard Rosen, director of the carotid endovascular program at Boston Scientific.


www.twincities.com

Use of stents in the carotid artery is just the latest migration of stent technology from the coronary artery to important arteries outside or "peripheral" to the heart, said Howard Rosen, director of the carotid endovascular program at Boston Scientific Corp.Rosen estimated that the overall market for stents in neck arteries eventually might reach $1 billion in value, although current sales are much lower.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory